One-Time Intravitreal Injection of KVD001, a Plasma Kallikrein Inhibitor, in Patients with Central-Involved Diabetic Macular Edema and Reduced Vision: An Open-Label Phase 1B Study
Publication information:
Sun J, Maturi R, Boyer D, Wells J, Gonzalez V, Tansley R, Hernandez H, Maetzel A, Feener E, Aiello LP. One-Time Intravitreal Injection of KVD001, a Plasma Kallikrein Inhibitor, in Patients with Central-Involved Diabetic Macular Edema and Reduced Vision: An Open-Label Phase 1B Study.
Ophthalmol Retina. 2019;3(12):1107–1109. PMID: 31810575